Clinical trial
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in…
NCT00002266 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00002266 |
|---|---|
| Title | An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients |
| Official title | An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | AS-101 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: